{"product_id":"ntla-bcg-matrix","title":"(NTLA) Intellia Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Intellia Therapeutics, Inc. BCG Matrix helps you quickly understand how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo true Stars yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia had no approved product revenue by end-2025, so it had no true Star in the classic BCG sense. Its closest Star-like assets were late-stage CRISPR programs, led by nexiguran ziclumeran and lonvoguran ziclumeran, which target large addressable markets but were still pre-commercial. In 2025, revenue was still only collaboration-based, not product sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-2001, ATTR amyloidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2001 is Intellia Therapeutics, Inc.'s lead in vivo CRISPR asset, and it has shown deep, one-dose serum TTR knockdown of about 90%+ in early studies. ATTR amyloidosis is a growing rare-disease market, with an estimated tens of thousands affected in the United States and clear unmet need. If safety, efficacy, and FDA execution hold, this is Intellia Therapeutics, Inc.'s clearest future Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-2002, hereditary angioedema\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-2002 is a late-stage in vivo gene-editing asset for hereditary angioedema, a rare disease affecting about 1 in 50,000 people. HAE is a small market, but it has high value because patients often need lifelong prophylactic therapy, so recurring demand is strong. If one-time dosing gives durable attack control, NTLA-2002 could win major share in a premium specialty niche. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIn vivo liver-editing platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.'s in vivo liver-editing platform is a Star because it uses one CRISPR\/Cas9 liver-delivery engine across several monogenic diseases, so each new program lowers reinvention risk. NTLA-2001 showed a mean 91% serum TTR reduction at 12 months in ATTR amyloidosis, proving the platform can cut deep in humans.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eOne liver-delivery engine, many indications\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBest proof point: 91% TTR cut at 12 months\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHigh growth, but heavy R\u0026amp;D spend\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHemophilia A and B programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.'s hemophilia A and B programs sit in a high-value rare-disease niche; hemophilia A affects about 1 in 5,000 male births and hemophilia B about 1 in 25,000. Regeneron co-development adds scale and outside validation, which strengthens the Stars case. If the gene-editing readouts hold, these programs could win a premium share in a multi-billion-dollar market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease, high pricing power\u003c\/li\u003e\n\u003cli\u003eRegeneron backs scale and credibility\u003c\/li\u003e\n\u003cli\u003eBig upside if clinical data hold\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s CRISPR Edge Hinges on Late-Stage Data\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. has no product-sales Star yet, but its lead in vivo CRISPR assets are the closest fit. NTLA-2001 showed about 91% serum TTR reduction at 12 months in ATTR, and NTLA-2002 targets hereditary angioedema, a rare but high-value market. The Star case depends on late-stage data, FDA execution, and durable one-dose outcomes.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStar case\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2001\u003c\/td\u003e\n\u003ctd\u003eStrongest\u003c\/td\u003e\n\u003ctd\u003e91% TTR cut\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-2002\u003c\/td\u003e\n\u003ctd\u003eHigh upside\u003c\/td\u003e\n\u003ctd\u003eHAE target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eIntellia’s BCG Matrix maps its gene-editing pipeline to spot stars, question marks, cash drains, and divest candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Intellia Therapeutics BCG Matrix that clarifies portfolio priorities and reduces strategic guesswork\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Intellia Therapeutics, Inc., helping validate key claims and support faster, more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo true Cash Cows yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics had no marketed product by end-2025, so it had no true Cash Cow or steady product-sales engine. Product revenue was still $0, and the company kept funding R\u0026amp;D with cash, collaboration income, and capital-market financing instead of mature operating cash flow. That fits a high-burn biotech profile, not a classic low-growth, high-share Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegeneron collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Regeneron collaboration is Intellia Therapeutics, Inc.'s key cash-supportive channel, with economics from research funding, milestones, and shared program value. It helps fund hemophilia work, but it is not a steady product annuity like a mature drug franchise. Intellia ended 2024 with $1.2 billion in cash, cash equivalents, and marketable securities, so this deal matters, but it is still a support engine, not the core cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNovartis collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNovartis remains a partner-backed value source for Intellia Therapeutics, Inc., supporting hematopoietic stem cell engineering work for sickle cell disease. This is still option value, not a true cash cow from sales: Intellia reported no product revenue from this tie-up, only collaboration support and milestone-style funding in its 2025 filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSparingVision alliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe SparingVision alliance broadens Intellia Therapeutics, Inc.'s reach in ocular genome medicine, but it is still more of a partnered option than a true cash cow. Intellia reported cash, cash equivalents, and marketable securities of $1.2 billion at June 30, 2025, so alliance cash helps fund R\u0026amp;D while limiting direct spend. \u003c\/p\u003e\n\u003cp\u003eUpfront and milestone payments can support revenue, but the market share signal is still absent because the asset is early and not commercial. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands ocular genome medicine reach\u003c\/li\u003e\n\u003cli\u003eBrings upfront and milestone cash\u003c\/li\u003e\n\u003cli\u003eLimits Intellia's direct spending\u003c\/li\u003e\n\u003cli\u003eMarket share is still not visible\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOspedale San Raffaele collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOspedale San Raffaele collaboration adds research depth and external validation for Intellia Therapeutics, Inc., but it is not a market-leading cash engine. Intellia ended 2024 with about $1.0 billion in cash, cash equivalents, and marketable securities, so this tie-up mainly supports science and non-product funding. It is useful cash support, not a mature Cash Cow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal scientific validation\u003c\/li\u003e\n\u003cli\u003eSupports non-product funding\u003c\/li\u003e\n\u003cli\u003eNot a mature cash generator\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia Has No Cash Cow—Just Partnerships and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc. has no true Cash Cow in its BCG mix because it had no marketed product and no product revenue through 2025. Its cash support comes from alliances like Regeneron, Novartis, SparingVision, and Ospedale San Raffaele, plus $1.2 billion in cash, cash equivalents, and marketable securities at June 30, 2025. These are funding sources, not mature, low-growth profit engines.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, cash equivalents, marketable securities\u003c\/td\u003e\n\u003ctd\u003e$1.2 billion at June 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStatus\u003c\/td\u003e\n\u003ctd\u003eNo marketed product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eIntellia Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Intellia Therapeutics, Inc. BCG Matrix report you’ll receive after purchase. The full document is the same professionally formatted file—no demo content, no hidden changes. Once purchased, it’s ready to download, review, and use for strategic analysis right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo true Dogs yet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, Intellia Therapeutics, Inc. still had no approved legacy brands, so there was no clear low-growth, low-share product to divest. Its weak spots were early-stage pipeline risk, not mature underperformers. The company reported $0 product revenue in 2025, so the Dogs bucket stayed empty.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-core exploratory programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s non-core exploratory programs sit outside its lead liver franchise, so they have low visibility and long timelines. In FY2024, Intellia still had no commercial product revenue, which makes these early assets harder to justify inside BCG terms unless they show clear data and partner pull. If they stay small and unfunded, they are the closest fit to Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly ex vivo oncology work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.'s early ex vivo oncology work fits Dogs: it is capital heavy, slow to de-risk, and crowded with CAR-T rivals. Ex vivo cell therapy programs often need $50M-$100M+ a year before pivotal data, so weak differentiation can drain cash fast if timelines slip.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic collaborations without product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic collaborations help Intellia Therapeutics, Inc. build CRISPR science, but they do not create product sales or real market share. In the latest reported period, revenue still came from collaborations and grants, not marketed drugs, so these ties stay weak as standalone BCG assets. They are best viewed as Question Marks, not Cash Cows.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNo commercial product revenue.\u003c\/li\u003e\n\u003cli\u003eScience value, weak scale.\u003c\/li\u003e\n\u003cli\u003eRevenue depends on partners.\u003c\/li\u003e\n\u003cli\u003eLow BCG strength alone.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDeprioritized platform bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIntellia Therapeutics has 2 lead late-stage assets, NTLA-2001 and NTLA-2002, so any pipeline work not tied to them is exposed to reprioritization. These side programs can still burn R\u0026amp;D cash without a near-term payoff, which makes them weak BCG Dogs if they do not move forward. In a $1B-plus development budget setting, management will likely protect the highest-value shots first.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 lead late-stage assets drive priority\u003c\/li\u003e\n\u003cli\u003eNon-core programs face R\u0026amp;D cuts\u003c\/li\u003e\n\u003cli\u003eNo advance, no Dog-zone escape\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s Dogs Bucket Stays Empty With No Product Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s Dogs bucket is mostly empty because there is no approved product, no product revenue in 2025, and no mature brand to harvest or divest. Any weak fit comes from small, non-core programs that burn cash without near-term scale, so they stay low-share, low-return assets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003e$0 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved drugs\u003c\/td\u003e\n\u003ctd\u003eNone\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore priority\u003c\/td\u003e\n\u003ctd\u003eNTLA-2001, NTLA-2002\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDog fit\u003c\/td\u003e\n\u003ctd\u003eWeak, non-core programs only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-3001, alpha-1 antitrypsin deficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-3001 is a low-share Question Mark because it is still developmental, but alpha-1 antitrypsin deficiency is a real rare-disease market, affecting about 1 in 2,000 to 1 in 5,000 people of European ancestry. If Intellia Therapeutics, Inc. proves durable liver edit results, the program could move toward Star status. Until then, it needs heavy R\u0026amp;D spend and clinical proof. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNTLA-5001, acute myeloid leukemia\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNTLA-5001 targets acute myeloid leukemia, a high-need market with about 20,000 new U.S. cases a year and poor 5-year survival near 30%. Intellia Therapeutics, Inc.’s ex vivo program is still early and has no commercial revenue, so its market share is effectively zero. That mix of big demand and low proof fits a classic Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHemophilia A and B, early market capture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHemophilia A and B remain an attractive market for Intellia Therapeutics, but the company still has no commercial share. As of 2025, its hemophilia assets are still in development, so value depends on clean clinical data, safety, and partner execution, not sales.\u003c\/p\u003e\n\u003cp\u003eThat keeps the segment a high-potential Question Mark: big upside, but no market access yet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOcular disease genome editing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOcular disease genome editing is a Question Mark for Intellia Therapeutics, Inc.: the SparingVision-linked chance is in a niche, science-led eye market, but it is still precommercial. There are no product sales yet, so market share is 0% today, even if the upside could be high if clinical data and partner execution hold.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh innovation, no sales\u003c\/li\u003e\n\u003cli\u003eZero share, early stage\u003c\/li\u003e\n\u003cli\u003eUpside depends on data\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEngineered cell therapies for oncology and autoimmune disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEngineered cell therapies for oncology and autoimmune disease sit in high-growth markets, but Intellia Therapeutics, Inc. is still pre-commercial here, with low share and no approved product revenue from these programs. That makes them classic Question Marks: large long-term upside, but they need heavy capital and clean clinical wins to move toward Star.\u003c\/p\u003e\n\u003cp\u003eNTLA’s cell-therapy effort must prove both safety and durable response in late-stage studies; until then, burn stays high and value stays tied to data. If one or more programs reaches approval in a market that can scale across thousands of patients, the share shift can be sharp.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-demand oncology and autoimmune markets\u003c\/li\u003e\n\u003cli\u003ePre-commercial, so share is still low\u003c\/li\u003e\n\u003cli\u003eNeeds major funding and clinical proof\u003c\/li\u003e\n\u003cli\u003eSuccess could re-rate the franchise fast\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellia’s High-Risk Pipeline Hinges on 2025-2026 Clinical Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIntellia Therapeutics, Inc.’s Question Marks are mostly precommercial programs with zero market share today, so value depends on 2025-2026 clinical proof, not sales. NTLA-3001, NTLA-5001, hemophilia, ocular, and cell therapy assets sit in high-need markets, but each still needs durable efficacy and safer editing before share can scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eMarket signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-3001\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eAATD: 1 in 2,000-5,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNTLA-5001\u003c\/td\u003e\n\u003ctd\u003eEarly\u003c\/td\u003e\n\u003ctd\u003eAML: ~20,000 U.S. cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHemophilia\/Ocular\/Cell\u003c\/td\u003e\n\u003ctd\u003ePrecommercial\u003c\/td\u003e\n\u003ctd\u003e0% share, high upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234765971721,"sku":"ntla-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ntla-bcg-matrix.webp?v=1785726790","url":"https:\/\/dcfanalyst.com\/products\/ntla-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}